3rd Annual Antibody Summit: Bispecifics & Multispecifics
23-24

May 2019

Vienna

Austria

Co-located with 4th Annual Antibody Drug Conjugates (ADCs) Summit: From Target to Therapeutics

We are pleased to invite you to the 3rd Annual Antibody Summit: Biscpecifics & Multispecifics scheduled for May 23 -24, 2019 in Vienna, Austria. This premier B2B event provides the appropriate platform to engage and discuss ideas with your fellow peers, while facilitating a professional atmosphere and environment for good company representation and development. The summit will shed light on the progress in discovery, development and therapeutics of novel protein therapeutics, and the latest breakthrough engineering next-generation antibody fo...

We are pleased to invite you to the 3rd Annual Antibody Summit: Biscpecifics & Multispecifics scheduled for May 23 -24, 2019 in Vienna, Austria. This premier B2B event provides the appropriate platform to engage and discuss ideas with your fellow peers, while facilitating a professional atmosphere and environment for good company representation and development. The summit will shed light on the progress in discovery, development and therapeutics of novel protein therapeutics, and the latest breakthrough engineering next-generation antibody formats. It is an honour and privilege to invite you to participate in this Summit. We look forward to welcoming you in Vienna in May!

more info
Who Should Attend

Chief Executives, Vice Presidents, Directors, Department Heads, Leaders, Managers, Clinical Development Experts and Scientists specialising in:

  • Antibody Discovery
  • Analytical & Formulation
  • Bioassay
  • Biologics
  • Cancer
  • CD3
  • Clinical trials / Development
  • CNS / Central Nervous System / Neuroscience
  • Drug Development
  • EGFR
  • Fc
  • Genetics
  • Immunogenicity
  • In silico modelling / quantitative science
  • Manufacturing
  • Multispecific Antibody
  • Oncology
  • Preclinical models
  • Process development / Developability
  • Protein Chemistry
  • T-cell
  • Theranostics
  • Toxicities / Toxicology
  • Yield
  • Antibody Engineering
  • BBB / Blood Brain Barrier
  • Biochemistry
  • Bispecifics
  • Cancer Immunotherapies
  • Checkpoint
  • CMC / Regulatory
  • Combination therapies
  • Drug targets / Targets selection
  • Ex vivo assay
  • FIH
  • Imaging
  • Immunology
  • mab
  • Monoclonal antibodies
  • Neuroscience
  • Pharmacokinetics (PK)
  • Process / Manufacturing quality
  • Protein
  • Screening / Modelling
  • Target toxities
  • Therapeutic antibodies
  • Tumours
Key Practical Learning Points of the Summit

CMC strategies for developing manufacturing processes and product quality characterization of bispecifics / multispecifics
Emerging approaches, science, and tech to engineer and to bring to market more targeted, stable, extended half-life, and functional multispecifics
Advanced analytical development and characterization for novel protein formats
Imaging, theranostic, and other new applications of bispecifics in oncology and beyond
Accelerating translation and clinical development progress of bispecific antibodies and combination therapies

Annual

Events

Sponsors and Partners

Media partner

Media partner